RT Journal Article
SR Electronic
T1 Nanopore Sequencing of SARS-CoV-2: Comparison of Short and Long PCR-tiling Amplicon Protocols
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.12.21256693
DO 10.1101/2021.05.12.21256693
A1 Brejová, Broňa
A1 Boršová, Kristína
A1 Hodorová, Viktória
A1 Čabanová, Viktória
A1 Gafurov, Askar
A1 Fričová, Dominika
A1 Neboháčová, Martina
A1 Vinař, Tomáš
A1 Klempa, Boris
A1 Nosek, Jozef
YR 2021
UL http://medrxiv.org/content/early/2021/05/13/2021.05.12.21256693.abstract
AB Surveillance of the SARS-CoV-2 variants including the quickly spreading mutants by rapid and near real-time sequencing of the viral genome provides an important tool for effective health policy decision making in the ongoing COVID-19 pandemic. Here we evaluated PCR-tiling of short (∼400-bp) and long (∼2 and ∼2.5-kb) amplicons combined with nanopore sequencing on a MinION device for analysis of the SARS-CoV-2 genome sequences. Analysis of several sequencing runs demonstrated that using the long amplicon schemes outperforms the original protocol based on the 400-bp amplicons. It also illustrated common artefacts and problems associated with this approach, such as uneven genome coverage, variable fraction of discarded sequencing reads, as well as the reads derived from the viral sub-genomic RNAs and/or human and bacterial contamination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe project was supported by grants from the Slovak Research and Development Agency (APVV-18-0239 to JN; PP-COVID-20-0017 to BK), the Scientific Grant Agency (VEGA 1/0463/20 to BB; VEGA 1/0458/18 to TV; VEGA 1/0027/19 to JN; VEGA 1/0136/20 to MN), and the European Union Horizon 2020 research and innovation program (EVA-GLOBAL project #871029 to BK and PANGAIA project #872539). The research was also supported in part by the Operation Program of Integrated Infrastructure (OPII) projects ITMS2014: 313011ATL7 and ITMS2014+: 313021X329 (Advancing University Capacity and Competence in Research, Development and Innovation), co-financed by the European Regional Development Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All clinical specimens used within this study were previously collected for the purpose of primary diagnosis of SARS-CoV-2 and were transferred to the Biomedical Research Center of the Slovak Academy of Sciences, Bratislava, Slovakia while made unidentifiable for the researchers performing this study. The study has been approved by the Ethics committee of Biomedical Research Center of the Slovak Academy of Sciences, Bratislava, Slovakia (Ethics committee statement No. EK/BmV-02/2020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe SARS-CoV-2 genome sequences determined in this study were deposited in the GISAID database (http://www.gisaid.org). The accession IDs are shown in S1 Table. The sequencing reads mapping to the reference genome were deposited to ENA under study PRJEB44303.